The Rising Burden of Polypharmacy: A Systemic Challenge Requiring Systemic Solutions

Polypharmacy — defined as the concurrent use of five or more prescription medications — has become one of the most pressing and underaddressed challenges in U.S. healthcare. Affecting nearly one in five American adults, its prevalence has more than doubled over the past two decades, rising from 8.2% to 17.1% between 1999 and 2018. As medication regimens grow more complex, so too do the associated risks: adverse drug events, preventable hospitalizations, functional decline, and a cost burden that extends well beyond the pharmacy counter. How do we address the masses who are inappropriately overmedicated?

While recent media attention has highlighted the problem of overmedication, polypharmacy isn’t simply the result of individual prescribing decisions. Understanding polypharmacy requires moving beyond individual prescribing decisions to examine the structural, clinical, and demographic forces that drive it. We can then focus on the evidence-based approaches that actually work to reduce its harm.

The Systemic Drivers of Polypharmacy

Polypharmacy is not, at its core, the result of individual clinical error. It is the predictable outcome of a healthcare system in which care is fragmented, chronic disease is prevalent, and medication reconciliation is inconsistently applied.

In a fragmented care environment, patients with complex conditions routinely receive care from multiple specialists across different settings and health systems. Each clinician may prescribe appropriately within the scope of their specialty, yet without a unified view of the patient's complete medication regimen, drugs accumulate incrementally and are rarely reassessed for ongoing appropriateness. This absence of systematic reconciliation allows medication lists to grow unchecked over time.

Prescribing cascades represent another significant contributor. When an adverse drug effect is misidentified as a new clinical condition, it frequently leads to an additional prescription rather than a reassessment of the original therapy. These cascades are especially common in older adults, where drug side effects can present atypically and are easily conflated with symptoms of aging or underlying disease.

Underlying both of these dynamics is the epidemiological reality of an aging population with high rates of multiple chronic conditions. Nearly 80% of adults over the age of 65 live with two or more chronic conditions, each typically managed according to disease-specific clinical guidelines that were not designed to account for the complexities of overlapping therapies. The combined medication burden this creates is substantial.

Populations at Elevated Risk

While polypharmacy affects patients across age groups and clinical profiles, several populations carry disproportionately higher risk.

Older adults are the most affected cohort, with approximately 44% of those aged 65 and older taking five or more prescription medications. Age-related changes in pharmacokinetics — including reduced renal clearance, altered hepatic metabolism, and decreased physiologic reserve — increase susceptibility to adverse drug events. Medications with sedating or anticholinergic properties are particularly hazardous in this population, contributing to falls, cognitive impairment, and functional decline.

Individuals with multiple chronic conditions face compounding medication-related risks. When therapies for conditions such as hypertension, diabetes, chronic kidney disease, and depression are managed in parallel without integrated oversight, the potential for drug–drug interactions, adherence failures, and prescribing cascades increases substantially.

Individuals with behavioral health conditions represent another clinically vulnerable population, particularly when psychiatric diagnoses co-occur with chronic pain or other medical conditions. Treatment often involves multiple psychotropic medications — including antidepressants, antipsychotics, mood stabilizers, anxiolytics, and sleep agents. They may also be combined with opioids or other central nervous system–active drugs. This layered prescribing increases the risk of sedation, metabolic complications, drug–drug interactions, and functional impairment.

A highly visible example is found with veterans and active-duty military population. Reporting by The Wall Street Journal has highlighted concerns about extensive psychotropic polypharmacy among veterans receiving care through the U.S. Department of Veterans Affairs. Service-related conditions — including PTSD, depression, traumatic brain injury, and chronic pain — frequently co-occur and are often managed with multiple psychotropic agents, sometimes in combination with opioids or other central nervous system–active medications. Research indicates that nearly half of this population is affected by polypharmacy overall, with veterans diagnosed with PTSD exhibiting more than double the rate of multiple psychotropic medications compared to those without the diagnosis. Fragmented care across military, VA, and civilian health systems further elevates risk.

The Clinical and Economic Cost

The downstream consequences of polypharmacy are measurable and significant. For older adults, high medication burden is associated with elevated rates of adverse drug events, falls, hospitalizations, and cognitive decline. Total annual healthcare costs for older adults with polypharmacy are approximately 65% higher than for those without it — roughly $14,700 compared to $8,900 per year.

When the analysis is broadened to include all non-optimized medication use — encompassing inappropriate drug selection, suboptimal dosing, unmanaged adverse effects, and poor adherence — the economic burden becomes considerably larger. Conservative estimates place the annual cost to the U.S. healthcare system at $528.4 billion, representing approximately 16% of total U.S. healthcare expenditure.

Evidence-Based Approaches to Medication Management

A range of clinical tools and care models have demonstrated meaningful impact in reducing polypharmacy-related harm. Several are increasingly central to high-quality medication management programs. However, most treatment guidelines focus on when to start therapy versus when to discontinue therapy — and how to do so safely.

The American Geriatrics Society Beers Criteria provides evidence-based guidance for identifying potentially inappropriate medications in older adults, with particular attention to drugs associated with age-related pharmacokinetic changes and elevated adverse event risk. The STOPP/START criteria complement this framework by prompting clinicians to evaluate not only which medications may warrant discontinuation, but also which evidence-based therapies may be absent from the regimen.

Deprescribing — the deliberate, evidence-informed tapering or discontinuation of medications — has gained substantial traction as a standard component of comprehensive medication management. When implemented as an ongoing clinical process rather than a reactive one-time intervention, and supported by shared decision-making between clinicians and patients, deprescribing has been shown to reduce medication burden safely and improve patient outcomes.

Quality measurement infrastructure is reinforcing these clinical priorities at a system level. CMS quality measures targeting high-risk medication use — including concurrent opioid and benzodiazepine (COB) prescribing and the use of multiple anticholinergic agents (Poly-ACH) — provide health plans and providers with actionable data to identify risk and drive performance improvement. Expanded eligibility criteria for Medication Therapy Management (MTM) programs further extends the reach of structured medication reviews to a broader patient population.

Pharmacist integration into interdisciplinary care teams has consistently demonstrated value across settings. Pharmacist-led medication reconciliation, MTM, and deprescribing support have been associated with reductions in medication counts, adverse drug event risk, and total cost of care.

Shifting to Outcomes-Driven Management at Scale

Despite measurable progress, most current approaches to polypharmacy management share a fundamental limitation: they are retrospective, episodic, and grounded in static clinical criteria.

Advancing the field requires shifting from a compliance-oriented framework to one centered on predicting and preventing real-world harm. Rather than flagging medications that may be inappropriate based on a set of criteria, Arine’s outcomes-driven medication management platform asks a more clinically relevant question: How likely is this patient to experience poor outcomes—and which medication changes will most reduce that risk? This is how we can achieve safer prescribing, better health, and measurable improvements in overall outcomes.

By applying AI models to longitudinal social, behavioral, and clinical data, Arine enables earlier identification of high-risk patients, more personalized clinical interventions, and the ability to measure performance by outcomes — hospitalizations prevented, adverse events avoided, total cost of care reduced — rather than process compliance alone. This model extends the value of medication management beyond patients who meet a formal definition of polypharmacy to encompass anyone whose medication regimen places them on a trajectory toward avoidable harm.

Medication oversight then evolves from a series of reactive safeguards into a proactive, outcomes-driven strategy focused not just on managing complexity, but on measurably improving safety, quality, and total cost of care.